About Us
Chairwoman of the Board, Executive Director: Ms. Theresa Tse
-
- Chairwoman of the Board, Executive Director: Ms. Theresa Tse
- Ms. Theresa Tse is the Chairwoman of the Board of Sino Biopharmaceutical Limited and Vice Chairwoman of CP Pharmaceutical Group since 2015. She is also the Director of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Vice Chairwoman of Beijing Tide Pharmaceutical Co.,Ltd. since 2017. Ms.Tse holds a Bachelor of Science Degree in Economics from the Wharton School of the University of Pennsylvania. Ms. Tse was included in the list of "100 Outstanding Business Women in China" by Forbes China for seven times from 2018 to 2025, and selected as one of "The Bloomberg 50" for 2024 by Bloomberg Businessweek.
Sino Biopharmaceutical Limited was listed on the Hong Kong Stock Exchange in 2000. Guided by the four main strategies of "organizational integration, comprehensive innovation, globalization, and digitalization", the Group focuses on innovation-driven transformation and accelerated international development. Under the leadership of Ms.Tse, Sino Biopharm became a constituent stock of the Hang Seng Index in 2018, and Hang Seng Connect Biotech 50 Index in 2020. It has been seven years in a row among the "Top 50 Global Pharmaceutical Enterprises" named by the US authoritative magazine Pharm Exec and was for three consecutive years among the "Asia's Fab 50 Companies" named by Forbes Asia. The Group upholds the concept of "Science for a healthier world". It currently focuses on four key strategic areas: oncology, liver diseases, respiratory, and surgery/analgesic, and has cumulatively served over 160 million patients. At the same time, the Group continues to increase its investment in innovative drug R&D annually, ranking us 15th globally in terms of pipeline scale.
The innovation transformation is now entering a harvest period, and more innovative products will be launched in the future to fill unmet clinical needs, hoping to provide more effective treatment options for more patients.
While adhering to innovative R&D, Ms. Tse has led Sino Biopharm to actively undertake social responsibilities and participate in various public welfare and charitable activities, implementing the principle of "benefiting the country, the people, and the enterprise". The company has continuously carried out activities in areas such as educational support, rural revitalization, and community welfare. In 2024, the total investment in public welfare amounted to over RMB 60 million . Under the leadership of Ms. Tse, the Group practices the mission of " "Enhancing Life Quality, Upholding Life Dignity". It has carried out multiple innovative ESG practices in corporate governance, environmental protection, and social responsibility, achieving excellent results. As of the end of 2024, the Group has received an "A" rating from the MSCI ESG ratings for two consecutive years.
*Portrait rights belong to the individual. Unauthorized use is prohibited.
-
Ms. Theresa Tse Invited to Attend 2025 International Biomedical Industry Innovation Conference Beijing Forum，Sino Biopharm's Frontier Technology Innovation R&D Center to be Established in International Pharmaceutical Innovation Park 2025.10
On the afternoon of October 25, the plenary session of the 2025 International Biomedical Industry Innovation Conference Beijing Forum was held with the theme "Innovation Without Borders, Health for a Shared Future".View > -
Ms. Theresa Tse Invited to Attend 2025 International Biomedical Industry Innovation Conference Beijing Forum，Sino Biopharm's Frontier Technology Innovation R&D Center to be Established in International Pharmaceutical Innovation Park 2025.10
On the afternoon of October 25, the plenary session of the 2025 International Biomedical Industry Innovation Conference Beijing Forum was held with the theme "Innovation Without Borders, Health for a Shared Future".View > -
Ms. Theresa Tse Attended Qisi Conference: Inflection Point for Domestic M&A in China's Pharmaceutical Industry Has Arrived, Sino Biopharm Embarks on a New Decade 2025.11
On November 25, the 17th China Pharmaceutical Entrepreneurs, Scientists and Investors Conference 2025 (hereinafter referred to as the "Qisi Conference") opened in Beijing.View > -
Xinhua Finance | Sino Biopharm's "Defu Combination" Releases Clinical Study Data 2025.05
Professor Shi Yuankai from the Cancer Hospital of the Chinese Academy of Medical Sciences stated that the regimen of Benmelstobart combined with chemotherapy followed by sequential combination with Anlotinib has broken through the bottleneck of traditional standard treatments and may change the existing treatment paradigm, providing an innovative first-line treatment model for patients with advanced squamous non-small cell lung cancer who have limited clinical treatment options.View > -
People's Daily Health | Nearly 30 Billion from Out-Licensing Deals! LaNova Medicines Acquired by Sino Biopharm 2025.07
After market close on July 15, Sino Biopharm announced that it will acquire a 95.09% stake in Shanghai-based LaNova Medicines for a total price of approximately USD 500 million. Combined with the 4.91% stake already acquired through participation in LaNova's Series C financing, LaNova Medicines will become a wholly-owned subsidiary of Sino Biopharm upon completion of the transaction.View > -
Xinhua News Agency | Sino Biopharm Reports 140.2% YoY Growth in H1 2025 Net Profit Attributable to Owners of the Parent 2025.08
Xinhua Finance, Nanjing, August 18 (Reporter: Zhu Cheng) - The 2025 semi-annual results report disclosed by Sino Biopharm on August 18 shows that the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion, representing year-on-year increases of 10.7% and 140.2%, respectively.View > -
Ta Kung Pao | Net Profit Doubles with 27.2% Surge in Innovative Product Revenue - Sino Biopharm Announces 2025 Interim Results 2025.08
Driven by the dual forces of policy support and innovation, the domestic pharmaceutical industry is accelerating its recovery. On August 18, Hong Kong-listed leading pharmaceutical company Sino Biopharm (01177.HK) announced its 2025 semi-annual results. In the first half of the year, the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion, representing year-on-year increases of 10.7% and 140.2%, respectively, marking three consecutive reporting periods of stable double-digit growth.View > -
Sino Biopharm 2024 Full-Year Results Announcement: Double-Digit Growth in Both Revenue and Net Profit, Innovative Product Revenue Exceeds 12 Billion, a New High 2025.03
On March 20, Sino Biopharm (HK.01177) released its 2024 annual results report, delivering an impressive "double-digit growth" across two key metrics: full-year revenue for 2024 reached RMB 28.87 billion, a year-on-year increase of 10.2%, hitting a record high; adjusted net profit attributable to owners of the parent company reached RMB 3.46 billion, a year-on-year increase of 33.5%.View > -
.jpg)
Listed for the Seventh Time, Ms. Theresa Tse Selected as one of "Forbes China's Outstanding Businesswomen" 2025.03
Recently, the 2025 "Forbes China's Top 100 Outstanding Businesswomen" list was officially released. Miss Theresa Tse, Chairwoman of the Board of Sino Biopharm (1177.HK), was named to the list, marking the seventh time she has been honored with this award.View > -
.jpg)
Ms. Theresa Tse Attended the 25th CIFIT: China's Pharmaceutical Innovation Momentum is Blooming, and Called for Mutually Beneficial Sino-Foreign Cooperation 2025.09
On September 8, the 25th China International Fair for Investment & Trade (CIFIT) grandly opened in Xiamen.View >